Drug Profile

Chimeric antigen receptor T cell therapy - Inceptor Bio

Alternative Names: CAR-T therapy - Inceptor Bio; Chimeric Antigen Receptor T Cell Therapy- Inceptor Bio

Latest Information Update: 06 Oct 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Inceptor Bio
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

30 Sep 2022 Preclinical trials in Cancer in USA (Parenteral) (Inceptor Bio pipeline, September 2022)
30 Sep 2022 Inceptor Bio plans a phase I trial for Cancer (Parenteral)
27 Oct 2021 Inceptor Bio announces intention to submit IND application for Cancer in early 2023 (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com